Why would a patient with metastatic cancer have a serum potassium of 5.8 mmol/L?

Hyperkalemia in Metastatic Cancer: Primary Causes

In a patient with metastatic cancer and a potassium of 5.8 mmol/L, you should immediately evaluate for tumor lysis syndrome (TLS), adrenal insufficiency from metastatic involvement, and medication effects—with TLS being the most urgent consideration if the patient is receiving or about to receive chemotherapy.

Key Diagnostic Framework

1. Tumor Lysis Syndrome (Most Critical)

TLS causes hyperkalemia through massive release of intracellular potassium during rapid tumor cell death 1, 2. This is your first consideration because:

• Laboratory TLS is defined as potassium ≥6.0 mmol/L (or >25% increase from baseline) occurring 3 days before to 7 days after starting anticancer treatment 2
• Your patient's K+ of 5.8 is approaching this threshold
• Clinical TLS requires laboratory abnormalities PLUS renal failure (eGFR ≤60 mL/min), cardiac arrhythmia, or seizures 2
• Symptoms typically occur 12-72 hours after chemotherapy initiation 1

Immediate actions:

• Check uric acid, phosphorus, calcium, and creatinine
• Calculate eGFR using MDRD formula 2
• Assess for cardiac arrhythmias, muscle cramps, paresthesias 1
• Determine if patient has high tumor burden, rapidly proliferative malignancy, or recent cytotoxic therapy

2. Adrenal Insufficiency from Metastatic Disease

Metastatic cancer can directly invade the adrenal glands, causing aldosterone deficiency and hyperkalemia 3, 4. This mechanism:

• Presents with isolated hyperkalemia when glucocorticoid axis is preserved (or patient is on steroids) 3
• Can occur with bilateral adrenal enlargement on imaging 3
• Is particularly relevant with immunotherapy-induced adrenalitis or hypophysitis 4

Diagnostic approach:

• Order morning cortisol and ACTH stimulation test
• Review abdominal CT/MRI for adrenal masses or enlargement
• Check medication list for checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab)

3. Pseudohyperkalemia (Common Pitfall)

Pseudohyperkalemia is particularly common in hematological malignancies 4 due to:

• Elevated white blood cell or platelet counts causing in vitro potassium release
• Mechanical trauma during blood draw in patients with fragile cells

Verification steps:

• Repeat potassium with plasma sample (not serum)
• Check CBC for extreme leukocytosis or thrombocytosis
• Ensure proper blood draw technique (no fist clenching, minimal tourniquet time)

Secondary Considerations

Medication-Related Causes

• ACE inhibitors, ARBs, potassium-sparing diuretics
• Trimethoprim, NSAIDs
• Heparin (suppresses aldosterone)

Renal Dysfunction

• Tumor-related obstructive uropathy
• Drug-induced nephrotoxicity (cisplatin, ifosfamide)
• Tumor infiltration of kidneys 1

Gastrointestinal Losses with Renal Compensation Failure

• While cancer patients often have hypokalemia from GI losses 5, concurrent renal failure prevents appropriate potassium excretion

Clinical Algorithm

Step 1: Determine timing relative to chemotherapy

• Within 3 days before to 7 days after treatment → TLS until proven otherwise
• Check uric acid, phosphorus, calcium, creatinine immediately 2

Step 2: If not TLS-related, obtain:

• Morning cortisol and ACTH
• Abdominal imaging review for adrenal involvement
• Repeat K+ with plasma to exclude pseudohyperkalemia

Step 3: Assess urgency based on:

• K+ >6.0 with ECG changes (peaked T waves, widened QRS) = medical emergency
• K+ 5.5-6.0 without ECG changes = urgent but not immediately life-threatening
• Presence of renal failure amplifies risk 2

Critical Pitfalls to Avoid

• Don't dismiss K+ 5.8 as "borderline" in cancer patients—it may herald TLS or adrenal crisis
• Don't assume all hyperkalemia is medication-related without excluding TLS and adrenal insufficiency
• Don't forget immunotherapy can cause delayed adrenal insufficiency (weeks to months after treatment) 4
• Don't overlook pseudohyperkalemia in hematologic malignancies—confirm with repeat testing 4

The most recent comprehensive review emphasizes that hyperkalemia in cancer patients has prognostic implications and requires prompt recognition of the underlying cause 4.